454
Views
0
CrossRef citations to date
0
Altmetric
Review

Aberrant regulation of CXCR4 in cancer via deviant microRNA-targeted interactions

, , &
Pages 2318-2331 | Received 25 Mar 2022, Accepted 18 Aug 2022, Published online: 06 Sep 2022
 

ABSTRACT

CXCR4 is involved in many facets of cancer, including being a major player in establishing metastasis. This is in part due to the deregulation of CXCR4, which can be attributed to many genetic and epigenetic mechanisms, including aberrant microRNA–CXCR4 interaction. MicroRNAs (miRNAs) are a type of small non-coding RNA that primarily targets the 3’ UTR of mRNA transcripts, which in turn suppresses mRNA and subsequent protein expression. In this review, we reported and characterized the many aberrant miRNA–CXCR4 interactions that occur throughout human cancers. In particular, we reported known target sequences located on the 3’ UTR of CXCR4 transcripts that tumour suppressor miRNAs bind and therefore regulate expression by. From these aberrant interactions, we also documented affected downstream genes/pathways and whether a particular tumour suppressor miRNA was reported as a prognostic marker in its respected cancer type. In addition, a limited number of cancer-causing miRNAs coined ‘oncomirs’ were reported and described in relation to CXCR4 regulation. Moreover, the mechanisms underlying both tumour suppressor and oncomir deregulations concerning CXCR4 expression were also explored. Furthermore, the miR-146a-CXCR4 axis was delineated in oncoviral infected endothelial cells in the context of virus-causing cancers. Lastly, miRNA-driven therapies and CXCR4 antagonist drugs were discussed as potential future treatment options in reported cancers pertaining to deregulated miRNA–CXCR4 interactions.

Key highlights

  • CXCR4 transcripts are targeted by tumour suppressor microRNAs and oncomirs in cancer.

  • The CXCR4-miRNA axis plays an important role in oncoviral function within the cell.

  • MiRNA ‘mimics’ and CXCR4 targeted antagonist therapeutics help in combating tumour progression.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability

was created using the UCSC Genome Browser.

Additional information

Funding

This study was supported by VA merit award 2I01BX000824 and National Cancer Institute RO3 awards CA249487; CA216160 to S.K.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.